Skip to main content
SpringerLink
Log in

Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer

  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

Ovarian malignancy is diagnosed in nearly a fourth of a million women internationally every year. Methylation of RASSF1A tumor suppressor gene prompts its inactivation in diseases. In this study, the RASSF1A promoter methylation was detected by methylated-specific PCR and investigated serum RASSF1A protein level through enzyme-linked immunosorbant assay in 160 Egyptian patients with ovarian cancer and 160 healthy controls. The present work proved that there was a higher frequency of RASSF1A methylation and a decrease in its serum level in patients with ovarian cancer compared to controls as well as in the high-grade tumor patients compared to low grade ones and also in advanced ovarian tumor stage compared to early stages. Our study exhibited that RASSF1A promoter hypermethylation and its protein levels may be a reliable and sensitive tool for diagnosing and monitoring of ovarian malignancy patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ozdemir, F., Altinisik, J., Karateke, A., Coksuer, H., & Buyru, N. (2012). Methylation of tumor suppressor genes in ovarian cancer. ExpTher Med, 4, 1092–1096.

    Article  CAS  Google Scholar 

  2. Zhang, Y., Guo, B., & Bi, R. (2012). Ovarian cancer: biomarker proteomic diagnosis in progress. Applied Biochemistry and Biotechnology, 168, 910–916.

    Article  CAS  Google Scholar 

  3. American Cancer Society. (2007). Cancer facts & figures. Atlanta: The Society.

    Google Scholar 

  4. Clarke-Pearson, D. L. (2009). Clinical practices. Screening for ovarian cancer. The New England Journal of Medicine, 361, 170–177.

    Article  CAS  Google Scholar 

  5. Board, R. E., Knight, L., Greystoke, A., Blackhall, F. H., Hughes, A., Dive, C., & Ranson, M. (2008). DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomarker Insights, 2, 307–319.

    Google Scholar 

  6. Aggarwal, M. R., Kumar, A., & Shrivastava, A. (2015). Natural compounds: DNA methyltransferase inhibitors in oral squamous cell carcinoma. Applied Biochemistry and Biotechnology, 177, 577–594.

    Article  Google Scholar 

  7. Sepulveda, A. R., Jones, D., Ogino, S., Samowitz, W., Gulley, M. L., Edwards, R., Levenson, V., Pratt, V. M., Yang, B., Nafa, K., Yan, L., & Vitazka, P. (2009). CpG methylation analysis–current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. The Journal of Molecular Diagnostics, 11, 266–278.

    Article  CAS  Google Scholar 

  8. Barton, C. A., Hacker, N. F., Clark, S. J., & O’Brien, P. M. (2008). DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecologic Oncology, 109, 129–139.

    Article  CAS  Google Scholar 

  9. Ibanez de Caceres, I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Research, 64, 6476–6481.

    Article  Google Scholar 

  10. Melnikov, A., Scholtens, D., Godwin, A., & Levenson, V. (2009). Differential methylation profile of ovarian cancer in tissues and plasma. The Journal of Molecular Diagnostics, 11, 60–65.

    Article  CAS  Google Scholar 

  11. Su, H. Y., Lai, H. C., Lin, Y. W., Chou, Y. C., Liu, C. Y., & Yu, M. H. (2009). An epigenetic markerpanel for screening and prognostic prediction of ovarian cancer. International Journal of Cancer, 124, 387–393.

    Article  CAS  Google Scholar 

  12. Leon, S. A., Shapiro, B., Sklaroff, D. M., & Yaros, M. J. (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Research, 37, 646–650.

    CAS  Google Scholar 

  13. Chmelarova, M., Dvorakova, E., Spacek, J., Laco, J., & Palicka, V. (2013). Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 157(4), 294–297.

    CAS  Google Scholar 

  14. Hesson, L. B., Cooper, W. N., & Latif, F. (2007). The role of RASSF1A methylation in cancer. Disease Markers, 23, 73–87.

    Article  CAS  Google Scholar 

  15. Lee, M. G., Kim, H. Y., Byun, D. S., Lee, S. J., Lee, C. H., Kim, J. I., Chang, S. G., & Chi, S. G. (2001). Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Research, 61, 6688–6692.

    CAS  Google Scholar 

  16. Donninger, H., Vos, M. D., & Clark, G. J. (2007). The RASSF1A tumor suppressor. Journal of Cell Science, 120, 3163–3172.

    Article  CAS  Google Scholar 

  17. Dammann, R., Schagdarsurengin, U., Seidel, C., Strunnikova, M., Rastetter, M., Baier, K., & Pfeifer, G. P. (2005). The tumor suppressor RASSF1A in human carcinogenesis: an update. Histology and Histopathology, 20, 645–663.

    CAS  Google Scholar 

  18. Pfeifer, G. P., Dammann, R., & Tommasi, S. (2010). RASSF proteins. Current Biology, 20, R344–R345.

    Article  CAS  Google Scholar 

  19. Ren, J., Singh, B. N., Huang, Q., Li, Z., Gao, Y., Mishra, P., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S. W. (2011). DNA hypermethylation as a chemotherapy target. Cellular Signalling, 23(7), 1082–1093.

    Article  CAS  Google Scholar 

  20. Landen, C. N., Birrer, M. J., & Sood, A. K. (2008). Early events in the pathogenesis of epithelial ovarian cancer. Journal of Clinical Oncology, 26, 995–1005.

    Article  Google Scholar 

  21. Huang, Z., Wen, Y., Shandilya, R., Marks, J. R., Berchuck, A., & Murphy, S. K. (2006). High through put detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Research, 34, 555–563.

    Article  CAS  Google Scholar 

  22. Harden, S. V., Tokumaru, Y., Westra, W. H., Goodman, S., Ahrendt, S. A., Yang, S. C., & Sidransky, D. (2003). Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clinical Cancer Research, 9, 1370–1375.

    CAS  Google Scholar 

  23. Jones, P. A., & Laird, P. W. (1999). Cancer epigenetics comes of age. Nature Genetics, 21, 163–167.

    Article  CAS  Google Scholar 

  24. Zhao, M., Sun, J., & Zhao, Z. (2012). Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer. PLoS One, 7, e44175.

    Article  CAS  Google Scholar 

  25. Jones, P. A., & Baylin, S. B. (2002). The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics, 3, 415–428.

    Article  CAS  Google Scholar 

  26. Xing, B. L., Li, T., Tang, Z. H., Jiao, L., Ge, S. M., Qiang, X., & OuYang, J. (2015). Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer. Genetics and Molecular Research, 4, 4532–4540.

    Article  Google Scholar 

  27. Montavon, C., Gloss, B. S., Warton, K., Barton, C. A., Statham, A. L., Scurry, J. P., Tabor, B., Nguyen, T. V., Qu, W., Samimi, G., Hacker, N. F., Sutherland, R. L., Clark, S. J., & O’Brien, P. M. (2012). Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecologic Oncology, 124, 582–588.

    Article  CAS  Google Scholar 

  28. Bhagat, R., Chadaga, S., Premalata, C. S., Ramesh, G., Pallavi, V. R., & Krishnamoorthy, L. (2012). Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cellular Oncology, 35, 473–479.

    Article  CAS  Google Scholar 

  29. Zhang, J., Xing, B., Song, J., Zhang, F., Nie, C., Jiao, L., Liu, L., Lv, F., & Wang, S. (2014). Associated analysis of DNA methylation for cancer detection using CCP-based FRET technique. Analytical Chemistry, 86, 346–350.

    Article  CAS  Google Scholar 

  30. Zuberi, M., Mir, R., Dholariya, S., Najar, I., Yadav, P., Javid, J., Guru, S., Mirza, M., Gandhi, G., Khurana, N., Ray, P. C., & Saxena, A. (2014). RASSF1 and PTEN promoter hypermethylation influences the outcome in epithelial ovarian cancer. Clin Ovarian and Other Gynecol Cancer, 7, 33–39.

    Article  Google Scholar 

  31. Matoo, A. A., Khan, H., Wani, H. A., Bhat, A. A., Habib, M., Bashir, H., Farooq, R., Rasheed, T., Naikoo, N. A., Zargar, M. A., Massood, A., & Majid, S. (2013). RAS association domain isoform a gene (RASSF1A) hypermethylation in ovarian cancer patients of Kashmir Valley. J Pak Med Stud, 3, 87–91.

    CAS  Google Scholar 

  32. Shi, H., Li, Y., Wang, X., Lu, C., Yang, L., Gu, C., Xiong, J., Huang, Y., Wang, S., & Lu, M. (2013). Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. PLoS One, 8, e76787.

    Article  CAS  Google Scholar 

  33. Fu, L. J., & Zhang, S. L. (2015). Expression of RASSF1A in epithelial ovarian cancers. Eur Rev Med PharmacolSci, 19, 813–817.

    Google Scholar 

  34. Pan, Y. M., Wu, Y. Z., Shi, Y. F., & Zhu, Z. Q. (2015). Methylation of tumor suppressor gene RASSF1A and BRCA1 in primary epithelial ovarian cancer. Scientific Research and Essays, 5(24), 3939–3944.

    Google Scholar 

  35. Giannopoulou, L., Chebout, I. I., Pavlakis, K., Kasimir-Bauer, S., & Lianidou, S. E. (2017). RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget, 8, 21429–21443.

    Article  Google Scholar 

  36. Gobel, G., Auer, D., Gaugg, I., Schneitter, A., Lesche, R., Muller-Holzner, E., Marth, C., & Daxenbichler, G. (2011). Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patient. Breast Cancer Research and Treatment, 130, 109–117.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Noha A. Rezk

  2. Biochemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt

    Rasha H. Mohamed

  3. Obstetrics and Gynecology Departments, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Amr AbdAlmohsen Alnemr & Mervat Harira

Authors
  1. Noha A. Rezk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rasha H. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amr AbdAlmohsen Alnemr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mervat Harira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noha A. Rezk.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

The ethics committee of Zagazig University approved this study (REC number Zu- 123432 I).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezk, N.A., Mohamed, R.H., Alnemr, A.A. et al. Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer. Appl Biochem Biotechnol 185, 153–162 (2018). https://doi.org/10.1007/s12010-017-2648-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12010-017-2648-4

Keywords

Search

Navigation